S&P Futures
4,004.50 -15.25 (-0.38%) Dow Futures
32,072.00 -48.00 (-0.15%) Nasdaq Futures
12,305.75 -77.00 (-0.62%) Russell 2000 Futures
1,782.50 -7.00 (-0.39%) Crude Oil
110.23 -0.26 (-0.24%) Gold
1,802.10 -6.10 (-0.34%)
Catalyst Biosciences, Inc. (CBIO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.3583 |
| Open | 0.3762 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 3200 |
| Day's Range | 0.3570 - 0.3851 |
| 52 Week Range | 0.3500 - 5.2000 |
| Volume | |
| Avg. Volume | 334,846 |
| Market Cap | 11.314M |
| Beta (5Y Monthly) | 1.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.0550 |
| Earnings Date | Mar 02, 2022 - Mar 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Aug 20, 2015 |
| 1y Target Est | 11.67 |
- GlobeNewswire
Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results
SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2022. “In the first quarter, we regained the rights to CB 2782-PEG, a C3 degrader protease, for the potential treatment of dry age-related macular degeneration (“AMD”) and now have full rights to two wholly-owned, potential best-in-class complement candidates that may provide compelling opportunities in o
- Simply Wall St.
Here's Why Catalyst Biosciences (NASDAQ:CBIO) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GlobeNewswire
Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update
SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update. “In late 2021 we announced a strategic change in corporate strategy, pivoting from hemophilia to a highly promising complement therapeutics and protease medicines platform,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. “T
